Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

108.97 -2.51 (-2.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
64 65 Next >
Recap: BioNTech Q4 Earnings
  BioNTech (NASDAQ:BNTX) reported its Q4 earnings results on Wednesday, March 30, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Omicron BA.2 Variant Represents More Than 50% COVID-19 Cases, Says CDC Estimates: WSJ
According to the Centers for Disease Control and Prevention estimates, the omicron BA.2 variant represents approximately 55% of new COVID-19 cases in the U.S., as signs suggest infections are edging... 
Via Benzinga
Novavax Stock Is a Bet on Interest From Unvaccinated People
NVAX stock represents a vaccine that lacks approval. There is real appeal behind the narrative, as it may appeal to unvaccinated people. 
Via InvestorPlace
A Peek Into The Markets: US Stock Futures Down Ahead Of GDP Report
Pre-open movers 
Via Benzinga
FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People
The FDA has approved a second round of the Moderna Inc (NASDAQ:  
Via Benzinga
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country 
Via Benzinga
Moderna, BioNTech Pop After FDA OKs Another Covid Booster Round — But Not For Everyone
But only some people will be eligible for a fourth dose of the shots at five months. 
Via Investor's Business Daily
Earnings Outlook For BioNTech
BioNTech (NASDAQ:BNTX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement. Analysts estimate that BioNTech will... 
Via Benzinga
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
From Pfizer Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers NexImmune (NASDAQ:NEXI) stock moved upwards by 8.3% to $3.51 during Monday's after-market session. This security traded at a volume of 109.1K shares come close, making up 76.6% of its average... 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight... 
Via FinancialNewsMedia
Exposures COVID-19
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection. 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
Biden Administration Contemplating Second COVID-19 Booster Shot Recommendation Within Weeks: Politico
The Biden administration could authorize a fourth dose or second COVID-19 booster shot for people aged 65 years and above within weeks, amid rising concern over a potential resurgence of cases,  
Via Benzinga
How Moderna Could Sneak By Pfizer, BioNTech With A Pediatric Covid Vaccine
Moderna unveiled promising data for a two-dose vaccine in children under age 6. 
Via Investor's Business Daily
Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6
Via Benzinga
FDA To Hold Advisory Committee Meeting To Discuss COVID-19 Vaccine Future Boosters
The FDA that a panel of independent advisers will meet on April 6 to discuss considerations for using COVID-19 vaccine booster doses. 
Via Benzinga
Will Another Covid Booster Save Vaccine Stocks Moderna, BioNTech?
Vaccine stocks remain under pressure despite a push for another round of Covid shots. 
Via Investor's Business Daily
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC
U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases. 
Via Benzinga
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,  
Via Benzinga
Is A Fourth Covid Shot Needed? Pfizer, Moderna Say Yes And Request It
Moderna just asked the FDA to sign off on another booster shot for all adults. 
Via Investor's Business Daily
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose
Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a  
Via Benzinga
Vaccine Makers Continue to Post Big Stock Price Gains
As Barron’s reports: “According to a data tracker from the New York Times, the daily average number of new cases in China is up more than 450% over the past two weeks.” 
Via Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC
The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren& 
Via Benzinga
White House Warns It Cannot Afford COVID-19 Related Solutions If Cases Increase: FT
The White House says that the U.S. is running out of money to pay for COVID-19 vaccines, tests, and treatments, making it unprepared for any rising cases in the future. 
Via Benzinga
Pfizer-BioNTech Seek FDA Approval For Second COVID-19 Booster In Elderly Population
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) filed an application with the  
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
64 65 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.